- OpenEvidence
OpenEvidence has signed content agreements with NEJM, JAMA, NCCN, Wiley, Cochrane, and more An Official AI Partner of The New England Journal of Medicine OpenEvidence content includes figures, tables, multimedia and full-text clinical findings from The New England Journal of Medicine
- OpenEvidence - Wikipedia
OpenEvidence is an American artificial intelligence company that develops a medical search engine used by physicians for clinical decision support The company was founded in 2022 by entrepreneur Daniel Nadler and is headquartered in Miami, Florida
- OpenEvidence - Apps on Google Play
OpenEvidence is the fastest-growing and most widely-used clinical decision support platform in the world–used daily, on average, by over 40% of physicians in the United States, spanning more than
- OpenEvidence - bond. libguides. com
OpenEvidence is a medical information platform designed to aggregate, synthesise and visualise clinically relevant evidence Launched from the Mayo Clinic Platform Accelerate program, it features multimedia and clinical findings from The New England Journal of Medicine
- OpenEvidence’s Meteoric Rise Is Huge For Doctors - Forbes
OpenEvidence, now having been trained on nearly 35 million peer reviewed publications, is aiming to automate these opportunities by democratizing the search for information
- OpenEvidence as Learning Tool
OpenEvidence is an AI-powered platform that aggregates, synthesizes, and visualizes peer reviewed medical literature in a format intended to be easily understood and support healthcare professionals in learning and making evidence-based decisions [1]
- OpenEvidence Safety and Comparative Efficacy of Four LLMs in Clinical . . .
OpenEvidence is an online tool that aggregates and synthesizes data from peer-reviewed medical studies, then producing a response to a user's questions using generative AI
- OpenEvidence: ChatGPT for Doctors 2026 Plans and Strategic Outlook
OpenEvidence entered 2026 on an extraordinary growth arc In January 2026, the Miami-based company closed a $250 Million Series D led by Thrive Capital and DST Global, doubling its valuation to
|